Precision Medicine Platform OncoHost offers PROphet®, a precision medicine platform that provides crucial guidance on optimal first-line immunotherapy for non-small cell lung cancer patients. This innovative tool presents a sales opportunity for healthcare institutions seeking to enhance personalized treatment decisions.

Global Clinical Trials With a large-scale prospective clinical trial involving over 40 sites and 1,700 patients worldwide, OncoHost is well-positioned to leverage its data and results to attract collaborations with healthcare providers, research institutions, and pharmaceutical companies looking to advance precision diagnostics and biomarker development.

Expansion into Renal Cell Carcinoma The recent launch of a study in partnership with Dana-Farber Cancer Institute to identify biomarkers for renal cell carcinoma (RCC) signals OncoHost's expansion into new areas of oncology. This initiative creates an opportunity for the company to engage with clinicians, researchers, and organizations interested in RCC biomarker discovery.

Presence in the U.S. Market The successful launch of the PROphet® NSCLC Cancer Test in the United States establishes OncoHost's presence in a key market. This milestone opens doors for collaborations with U.S.-based healthcare providers, oncologists, and medical centers seeking innovative diagnostic solutions for cancer care.

Industry Recognition OncoHost's recognition at the 2023 BIG Innovation Awards highlights its leadership in precision oncology. This accolade not only reinforces the company's credibility but also offers a sales advantage by demonstrating expertise and innovation to potential partners, investors, and customers in the healthcare sector.